BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

751 related articles for article (PubMed ID: 37041165)

  • 1. Oncolytic virotherapy: basic principles, recent advances and future directions.
    Lin D; Shen Y; Liang T
    Signal Transduct Target Ther; 2023 Apr; 8(1):156. PubMed ID: 37041165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.
    Tian Y; Xie D; Yang L
    Signal Transduct Target Ther; 2022 Apr; 7(1):117. PubMed ID: 35387984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
    Wei D; Xu J; Liu XY; Chen ZN; Bian H
    Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions.
    Vazaios K; van Berkum RE; Calkoen FG; van der Lugt J; Hulleman E
    Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
    Workenhe ST; Verschoor ML; Mossman KL
    Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.
    Yun CO; Hong J; Yoon AR
    Front Immunol; 2022; 13():953410. PubMed ID: 36091031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and application of oncolytic viruses for cancer immunotherapy.
    Ylösmäki E; Cerullo V
    Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
    Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
    Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment.
    Chattopadhyay S; Hazra R; Mallick A; Gayen S; Roy S
    Biochim Biophys Acta Rev Cancer; 2024 Jul; 1879(4):189110. PubMed ID: 38754793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Viruses and Cancer Immunotherapy.
    Malhotra J; Kim ES
    Curr Oncol Rep; 2023 Jan; 25(1):19-28. PubMed ID: 36441447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of oncolytic virus in tumor therapy.
    Huang Z; Guo H; Lin L; Li S; Yang Y; Han Y; Huang W; Yang J
    J Med Virol; 2023 Apr; 95(4):e28729. PubMed ID: 37185868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.
    Volovat SR; Scripcariu DV; Vasilache IA; Stolniceanu CR; Volovat C; Augustin IG; Volovat CC; Ostafe MR; Andreea-Voichița SG; Bejusca-Vieriu T; Lungulescu CV; Sur D; Boboc D
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virotherapy: From single agents to combinatorial treatments.
    Malfitano AM; Di Somma S; Iannuzzi CA; Pentimalli F; Portella G
    Biochem Pharmacol; 2020 Jul; 177():113986. PubMed ID: 32330494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in oncolytic virus-based cancer therapy.
    Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
    Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research Advances of Clinical Application of Oncolytic Viruses in Treatment of Gynecologic Cancers.
    Deng M; Wang Q
    Curr Cancer Drug Targets; 2023; 23(7):505-523. PubMed ID: 36824004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The two-faces of NK cells in oncolytic virotherapy.
    Marotel M; Hasim MS; Hagerman A; Ardolino M
    Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of oncolytic virotherapy: from genetic modification to combination therapy.
    Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
    Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark.
    Muscolini M; Tassone E; Hiscott J
    Cytokine Growth Factor Rev; 2020 Dec; 56():94-101. PubMed ID: 32826166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?
    Zhang S; Rabkin SD
    Expert Opin Drug Discov; 2021 Apr; 16(4):391-410. PubMed ID: 33232188
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 38.